Should Cytochrome P450 Inducers be Used to Accelerate Clearance of Brodifacoum from Poisoned Patients?

Abstract A recent multi-state outbreak of life-threatening bleeding following inhalation of synthetic cannabinoids has been attributed to contamination with the long-acting anticoagulant rodenticide (LAAR) brodifacoum, a second-generation, highly potent, long-acting derivative of the commonly used b...

Full description

Saved in:
Bibliographic Details
Main Authors: Israel Rubinstein (Author), Richard van Breemen (Author), Daniel G. Nosal (Author), Guy Weinberg (Author), Ronald C. Hershow (Author), Douglas L. Feinstein (Author)
Format: Book
Published: Adis, Springer Healthcare, 2019-01-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_e20f4ca682714b6a854ca8e11188b24f
042 |a dc 
100 1 0 |a Israel Rubinstein  |e author 
700 1 0 |a Richard van Breemen  |e author 
700 1 0 |a Daniel G. Nosal  |e author 
700 1 0 |a Guy Weinberg  |e author 
700 1 0 |a Ronald C. Hershow  |e author 
700 1 0 |a Douglas L. Feinstein  |e author 
245 0 0 |a Should Cytochrome P450 Inducers be Used to Accelerate Clearance of Brodifacoum from Poisoned Patients? 
260 |b Adis, Springer Healthcare,   |c 2019-01-01T00:00:00Z. 
500 |a 10.1007/s40268-019-0261-4 
500 |a 1174-5886 
500 |a 1179-6901 
520 |a Abstract A recent multi-state outbreak of life-threatening bleeding following inhalation of synthetic cannabinoids has been attributed to contamination with the long-acting anticoagulant rodenticide (LAAR) brodifacoum, a second-generation, highly potent, long-acting derivative of the commonly used blood thinner warfarin. While long-term treatment with high-dose vitamin K1 restores coagulation, it does not affect brodifacoum metabolism or clearance, and, consequently, brodifacoum remains in the human body for several months, thereby predisposing to risk of bleeding recurrence and development of coagulation-independent injury in extrahepatic tissues and fetuses. This has prompted the evaluation of pharmacological measures that accelerate brodifacoum clearance from poisoned patients. Since the induction of certain cytochrome P450 (CYP) enzymes accelerates warfarin metabolism, using CYP inducers, such as phenobarbital, to accelerate brodifacoum clearance seems plausible. However, unlike warfarin, brodifacoum does not undergo significant metabolism in the liver, nor have the effects of phenobarbital on vitamin K1 metabolism been previously determined. In addition, the safety of phenobarbital in brodifacoum-poisoned patients has not been established. Therefore, we propose that CYP inducers should not be used to accelerate the clearance of brodifacoum from poisoned patients, but that alternative approaches such as reducing enterohepatic recirculation of brodifacoum, or using lipid emulsions to scavenge brodifacoum throughout the body, be considered. 
546 |a EN 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Drugs in R&D, Vol 19, Iss 1, Pp 67-71 (2019) 
787 0 |n http://link.springer.com/article/10.1007/s40268-019-0261-4 
787 0 |n https://doaj.org/toc/1174-5886 
787 0 |n https://doaj.org/toc/1179-6901 
856 4 1 |u https://doaj.org/article/e20f4ca682714b6a854ca8e11188b24f  |z Connect to this object online.